The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...

Qure (NASDAQ:QURE) shares added ~39% in the premarket on Thursday after the Dutch biotech announced that the FDA granted ...

The original PROOF-HD trial of pridopidine was negative, but a new analysis showed it has clinically meaningful effects in ...

AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.

The number of people who have the gene that causes Huntington's disease in Northern Scotland has been accurately counted for ...

The neurodegenerative disease slowly damages the brain, taking away the ability to walk, talk, eat, drink, make decisions and ...

Sandy Patience says he is 'proud to break the mould' and take part in a clinical trial to develop treatments for Huntington's ...

Qure (QURE) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to AMT-130 for the treatment ...

Factors driving the market include rising disease prevalence, innovative therapies, and gene-based treatment breakthroughs. Key players like H Lundbeck and Pfizer are fueling research and development ...

today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington’s disease, a rare, inherited ...

Qure's AMT-130 receives FDA Breakthrough Therapy designation for Huntington's disease, adding to Fast Track, RMAT, and Orphan ...